Introduction
Fertility preservation (FP) remains a critical concern for young women diagnosed with breast cancer (YWBC). As advances in cancer treatments improve survival rates, attention to quality of life issues, including reproductive health, has gained prominence. Chemotherapy, while effective against cancer, poses risks of infertility and premature ovarian insufficiency (POI). Strategies such as cryopreservation of oocytes, embryos, or ovarian tissue and temporary ovarian suppression with gonadotropin-releasing hormone agonists (GnRHa) have been developed to mitigate these risks.
Despite the proliferation of these options, utilization varies widely due to factors like healthcare infrastructure, socioeconomic status, cultural societal norms, and patient awareness. The joint analysis of the Joven & Fuerte and PREFER prospective studies provides valuable insights into real-world practices across Mexico and Italy, two contrasting healthcare systems, and highlights the global disparities and common challenges in providing comprehensive fertility care to YWBC.
